Visum Pharmaceutical Co., Ltd.

Visum Pharmaceutical Co., Ltd., established in 2010 and based in Haikou, Hainan, manufactures finished-dosage pharmaceuticals with a focus on modified-release technology, producing agomelatine tablets, tacrolimus capsules, and extended-release formulations of paroxetine and metoprolol succinate. The company reports production capacity of roughly 3 billion tablets, 500 million capsules, 100 million units of oral solution, 50 million semi-solid units, and 500 million units of granules/powder for oral suspension annually, with technical expertise in solubility enhancement and modified-release approaches such as pellets-in-tablets/capsules, matrix, bilayer, and functional coating systems. Exporting about 40% of output on FOB and EXW terms, it offers CMO and CDMO contract manufacturing under OEM and own-brand arrangements, counts customers including BrightGene, Kintor Pharmaceutical, Regor Therapeutics, and CSPC, and sells into North America, Central/South America, Asia, the Middle East, and Australasia.